Akari Therapeutics (AKTX) Stock Forecast, Price Target & Predictions
AKTX Stock Forecast
Akari Therapeutics stock forecast is as follows: an average price target of $30.00 (represents a 2900.30% upside from AKTX’s last price of $1.00) and
AKTX Price Target
Akari Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 05, 2022 | H.C. Wainwright | $30.00 | $10.77 | 178.55% | 2900.30% |
The latest Akari Therapeutics stock forecast, released on Dec 05, 2022 by H.C. Wainwright company, set a price target of $30.00, which represents a 178.55% increase from the stock price at the time of the forecast ($10.77), and a 2900.30% increase from AKTX last price ($1.00).
Akari Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.00 | $1.00 | $1.00 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Akari Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akari Therapeutics's last price of $1.00. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Akari Therapeutics Financial Forecast
Akari Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | - |
| Surprise % | - | - | - |
Akari Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AKTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Akari Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict AKTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akari Therapeutics's previous annual EBITDA (undefined) of $NaN.
Akari Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| Net Income | - | - | - |
| Avg Forecast | $-12.19M | $-7.32M | $-9.42M |
| High Forecast | $-12.19M | $-7.32M | $-9.42M |
| Low Forecast | $-12.19M | $-7.32M | $-9.42M |
| Surprise % | - | - | - |
Akari Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akari Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Akari Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AKTX last annual SG&A of $NaN (undefined).
Akari Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|
| # Analysts | - | - | - |
| EPS | - | - | - |
| Avg Forecast | $-1.00 | $-0.60 | $-1.00 |
| High Forecast | $-1.00 | $-0.60 | $-1.00 |
| Low Forecast | $-1.00 | $-0.60 | $-1.00 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Akari Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKTX previous annual EPS of $NaN (undefined).